[go: up one dir, main page]

TNSN99095A1 - 4 - phenylpiperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant - Google Patents

4 - phenylpiperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant

Info

Publication number
TNSN99095A1
TNSN99095A1 TNTNSN99095A TNSN99095A TNSN99095A1 TN SN99095 A1 TNSN99095 A1 TN SN99095A1 TN TNSN99095 A TNTNSN99095 A TN TNSN99095A TN SN99095 A TNSN99095 A TN SN99095A TN SN99095 A1 TNSN99095 A1 TN SN99095A1
Authority
TN
Tunisia
Prior art keywords
preparation
pharmaceutical compositions
compositions containing
phenylpiperidines
new
Prior art date
Application number
TNTNSN99095A
Other languages
English (en)
Inventor
Edward Armer Richard
James Dutton Christopher
Morris Gethin David
Paul Gibson Stephen
Duncan Smith Julian
Tommasini Ivan
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of TNSN99095A1 publication Critical patent/TNSN99095A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C07D211/28—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/94—Oxygen atom, e.g. piperidine N-oxide

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'INVENTION CONCERNE DES COMPOSES NOUVEAUX DE FORMULE GENERALE (I) : DANS LAQUELLE R1, R2, R3, W, Y1, Y2 ET X REPRESENTENT DIVERS RADICAUX, n EST EGAL A 0,1 OU 2 ET Y EST EGAL A 0 OU 1. ELLE CONCERNE EGALEMENT DES PROCEDES POUR LEUR PREPARATION ET DES INTERMEDIAIRES UTILISES A CETTE FIN, AINSI QUE DES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT. APPLICATION : UTILISATION DE CES COMPOSES ET COMPOSITIONS POUR LE TRAITEMENT DE DERMATOSES PRURIGINEUSES CHEZ LES ANIMAUX ET L'HOMME.
TNTNSN99095A 1998-05-18 1999-05-17 4 - phenylpiperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant TNSN99095A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9810671.9A GB9810671D0 (en) 1998-05-18 1998-05-18 Anti-pruritic agents

Publications (1)

Publication Number Publication Date
TNSN99095A1 true TNSN99095A1 (fr) 2005-11-10

Family

ID=10832267

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN99095A TNSN99095A1 (fr) 1998-05-18 1999-05-17 4 - phenylpiperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant

Country Status (18)

Country Link
US (1) US6610711B2 (fr)
EP (1) EP1077940B1 (fr)
JP (1) JP2002515486A (fr)
AP (1) AP9901535A0 (fr)
AT (1) ATE271038T1 (fr)
AU (1) AU3531299A (fr)
BR (1) BR9910609A (fr)
CA (1) CA2332538C (fr)
DE (1) DE69918687T2 (fr)
DK (1) DK1077940T3 (fr)
ES (1) ES2230846T3 (fr)
GB (1) GB9810671D0 (fr)
GT (1) GT199900067A (fr)
MA (1) MA26630A1 (fr)
PT (1) PT1077940E (fr)
TN (1) TNSN99095A1 (fr)
WO (1) WO1999059971A1 (fr)
ZA (1) ZA993364B (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9912416D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912413D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912415D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912411D0 (en) * 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912410D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912417D0 (en) * 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
IL159697A0 (en) * 2001-07-05 2004-06-20 Synaptic Pharma Corp Substituted anilinic piperidines as mch selective antagonists
US6727264B1 (en) 2001-07-05 2004-04-27 Synaptic Pharmaceutical Corporation Substituted anilinic piperidines as MCH selective antagonists
IL161157A0 (en) * 2001-10-22 2004-08-31 Pfizer Prod Inc 3-azabicyclo (3.1.0) hexane derivatives as opioid receptor antagonists
KR20050044533A (ko) * 2001-11-19 2005-05-12 엘란 파마슈티칼스, 인크. 알츠하이머병을 치료하기 위한 베타-세크레타아제억제제로서의（４-페닐）피페리딘-３-일-페닐카르복실레이트유도체 및 관련 화합물
ES2201908B1 (es) * 2002-05-29 2005-02-16 Laboratorios Del Dr. Esteve, S.A. Pienso suplementado con ketoprofeno y su empleo en el tratamiento de procesos que cursan con fiebre, inflamacion y/o dolor, en un colectivo de animales, de forma simultanea.
MXPA05011070A (es) * 2003-04-14 2005-12-12 Pfizer Prod Inc Derivados de 3-azabiciclo [3.2.1] octano.
FR2872416B1 (fr) * 2004-07-01 2006-09-22 Oreal Utilisation de derives de piperidine pour lutter contre les rides
WO2006089082A2 (fr) * 2005-02-17 2006-08-24 Velcera Pharmaceuticals Administration par voie transmuqueuse de compositions medicamenteuses pour le traitement et la prevention de troubles chez les animaux
WO2007070760A2 (fr) * 2005-12-15 2007-06-21 Boehringer Ingelheim International Gmbh Composes qui modulent le recepteur cb2
MY145633A (en) 2006-03-01 2012-03-15 Theravance Inc 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
CA2657247A1 (fr) * 2006-07-28 2008-01-31 Boehringer Ingelheim International Gmbh Composes modulant le recepteur cb2
EP2074084B1 (fr) * 2006-09-25 2013-08-28 Boehringer Ingelheim International GmbH Composés modulant le recepteur cb2
TWI409067B (zh) * 2007-02-28 2013-09-21 Theravance Inc ８-氮雜雙環〔３．２．１〕辛烷化合物之結晶型
US7902221B2 (en) * 2007-08-27 2011-03-08 Theravance, Inc. Amidoalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
EP2195314B1 (fr) * 2007-08-27 2011-03-23 Theravance, Inc. Composes d'alkyl-8-azabicyclo[3.2.1.]octane disubstitutes utilises en tant qu'antagonistes du recepteur opioide mu
TWI423801B (zh) 2007-08-27 2014-01-21 Theravance Inc 作為μ類鴉片受體拮抗劑之８－氮雜雙環〔３．２．１〕辛基－２－羥基苯甲醯胺化合物
ES2465621T3 (es) * 2007-08-27 2014-06-06 Theravance, Inc. Compuestos de heteroarilalquil-8-azabiciclo[3.2.1]octano, como antagonistas de los receptores opiodes mu
CA2704684A1 (fr) * 2007-11-07 2009-05-14 Boehringer Ingelheim International Gmbh Composes modulant le recepteur cb2
WO2010005782A1 (fr) * 2008-07-10 2010-01-14 Boehringer Ingelheim International Gmbh Composés sulfones qui modulent le récepteur cb2
CN102164916A (zh) * 2008-09-25 2011-08-24 贝林格尔.英格海姆国际有限公司 选择性调节cb2受体的磺酰基化合物
US8299103B2 (en) * 2009-06-15 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
EP2443107B1 (fr) 2009-06-16 2018-08-08 Boehringer Ingelheim International GmbH Dérivés d'azétidine 2-carboxamide qui modulent le récepteur cb2
JP2013505295A (ja) * 2009-09-22 2013-02-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を選択的に調節する化合物
EP2523936A1 (fr) 2010-01-15 2012-11-21 Boehringer Ingelheim International GmbH Composés qui modulent le récepteur cb2
JP5746228B2 (ja) 2010-03-05 2015-07-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を選択的に調節するテトラゾール化合物
US8846936B2 (en) 2010-07-22 2014-09-30 Boehringer Ingelheim International Gmbh Sulfonyl compounds which modulate the CB2 receptor
EP2803668A1 (fr) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Nouveau (cyano-dimethyl-methyl)-isoxazoles et - [1,3,4] thiadiazoles
CN106278914B (zh) * 2016-08-19 2018-04-13 四川福思达生物技术开发有限责任公司 一种增产胺的合成工艺
CN116440882B (zh) * 2023-01-16 2024-09-20 浙江纽龙合成材料制造有限公司 一种基于端烯基活化的疏水分离层析介质及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR206937A1 (es) * 1974-09-06 1976-08-31 Lilly Co Eli Procedimiento para preparar compuestos de 1-sustituido-4-alquil-4-fenil-piperidina
ATE110057T1 (de) * 1987-04-16 1994-09-15 Lilly Co Eli Piperidine als opioid-antagoniste.
NZ242117A (en) * 1991-03-29 1994-11-25 Lilly Co Eli 4-phenylpiperidine derivatives and medicaments containing them
US5159081A (en) * 1991-03-29 1992-10-27 Eli Lilly And Company Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists
GB9507203D0 (en) * 1995-04-07 1995-05-31 Smithkline Beecham Plc Novel compounds
DZ2376A1 (fr) * 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
JP2001526643A (ja) * 1997-04-18 2001-12-18 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５ｈｔ１ａ、５ｈｔ１ｂおよび５ｈｔ１ｄ受容体アンタゴニスト活性を合わせ持つ化合物を含む二環式アリールまたは二環式複素環

Also Published As

Publication number Publication date
GB9810671D0 (en) 1998-07-15
DE69918687T2 (de) 2005-07-28
ES2230846T3 (es) 2005-05-01
AP9901535A0 (en) 1999-06-30
ZA993364B (en) 2000-12-01
EP1077940A1 (fr) 2001-02-28
CA2332538C (fr) 2005-08-02
AU3531299A (en) 1999-12-06
BR9910609A (pt) 2001-01-09
DK1077940T3 (da) 2004-11-01
GT199900067A (es) 2000-11-04
EP1077940B1 (fr) 2004-07-14
ATE271038T1 (de) 2004-07-15
MA26630A1 (fr) 2004-12-20
WO1999059971A1 (fr) 1999-11-25
PT1077940E (pt) 2004-10-29
JP2002515486A (ja) 2002-05-28
DE69918687D1 (de) 2004-08-19
CA2332538A1 (fr) 1999-11-25
US6610711B2 (en) 2003-08-26
US20030078282A1 (en) 2003-04-24

Similar Documents

Publication Publication Date Title
TNSN99095A1 (fr) 4 - phenylpiperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99106A1 (fr) Derives d'isothiazole nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN99172A1 (fr) 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN96172A1 (fr) Composes heterocycliques, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN01091A1 (fr) Derives bicycliques nouveaux, compositions les contenant et leur utilisation pour le traitement d'une croissance cellulaire anormale
TNSN00092A1 (fr) Composes nouveaux antagonistes de npy, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98238A1 (fr) Macrolides nouveaux
TNSN98194A1 (fr) Derives nouveaux de 6-o-methylerythromycine a, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98084A1 (fr) Derives de macrolides substitues en position c-4
TNSN99253A1 (fr) Composes chimiques nouveaux modulateurs de ccr5, et compositions pharmaceutiques les contenant.
TNSN99171A1 (fr) 4-carboxyamino-2-substitue-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99006A1 (fr) 4-(2-ceto-1-benzimidazolinyl) piperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN02022A1 (fr) Triazolopyridines anti-inflammatoires nouvelles, et compositions les contenant
TNSN00228A1 (fr) Derives de benzimidazole nouveaux, et compositions les contenant
TN2009000138A1 (fr) Biaryl-ether-urees
MA26697A1 (fr) Composes nouveaux inhibiteurs de gsk-3 et compositions pharmaceutiques les contenant
TNSN98154A1 (fr) Derives de 2-aminopyridine nouveaux et compositions pharmaceutiques les contenant
TNSN02008A1 (fr) Derives d'acides isophtalique nouveaux inhibiteurs de mmp, et compositions les contenant
TNSN97110A1 (fr) Derives de 2-(2-oxo-ethylidene)-imidazolidine-4-one, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99053A1 (fr) Hydroxamides d'acides (4-arylsulfonylamino)-tetrahydro- pyranne-4-carboxyliques), procede pour leur preparation et compositions les contenant
TNSN98203A1 (fr) Derives de thienopyrimidine et tienopyridine utiles comme agents anticancereux, et compositions les contenant
TNSN00036A1 (fr) Acides oxamiques nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN97198A1 (fr) Derives de 6-phenylpyridyl-2- amine et compositions pharmaceutiques les contenant
TNSN99055A1 (fr) Derives bicycliques d'acide hydroxamique nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN01102A1 (fr) Derives de pyrazole nouveaux, procede pour leur preparation et compositions les contenant.